Sources and Guidelines Referenced

The clinical recommendations and outcomes in this guide are derived from published practice guidelines and peer-reviewed urologic studies, including:

• EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (European Association of Urology, 2023)
• AUA/SUO Guideline on Non-Muscle Invasive Bladder Cancer (American Urological Association / Society of Urologic Oncology, 2020, amended 2024)
• NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (National Comprehensive Cancer Network, Version 2.2024)
• Sylvester et al., European Urology (2016, Meta-analysis on single immediate intravesical instillation)
• Babjuk et al., European Urology (2022, EAU updates on NMIBC management)
• Chang et al., Journal of Urology (2016, Diagnosis and treatment of non-muscle invasive bladder cancer)

Cystoscopy & TURBT (Bladder Tumor Resection): A Comprehensive Patient Guide

1. Definition and Medical Identity

Cystoscopy and transurethral resection of bladder tumor, commonly referred to as TURBT, is a endoscopic surgical procedure used to diagnose, stage, and treat abnormal growths within the urinary bladder. The procedure utilizes a specialized optical scope passed through the urethra, allowing direct visual inspection and precise surgical removal of bladder tissue without external abdominal incisions.

In the field of urology and urologic oncology, cystoscopy serves as the primary diagnostic imaging modality for lower urinary tract pathology, while TURBT functions as both a diagnostic biopsy tool and the initial therapeutic intervention for suspected urothelial neoplasms. The full technical term includes diagnostic cystourethroscopy followed by transurethral electrosurgical resection or fulguration of bladder tissue. The principal clinical objective is achieving complete macroscopical excision of all visible bladder tumors while securing adequate structural sampling of the underlying bladder wall to guide definitive oncological management.

2. Underlying Condition or Need

Bladder cancer is among the most prevalent malignancies of the urinary system, originating predominantly within the specialized cellular lining known as the urothelium. When genetic alterations cause urothelial cells to multiply uncontrollably, they form abnormal growths or lesions that project into the bladder cavity (papillary tumors) or spread as flat, aggressive mucosal lesions known as carcinoma in situ (CIS).

The classic clinical presentation of an underlying bladder neoplasm is painless gross hematuria (visible blood in the urine), which occurs in over 80% of affected individuals. Other patients present with microscopic hematuria discovered during routine urinalysis, or irritative voiding symptoms such as dysuria (painful urination), severe urinary urgency, and increased urinary frequency that persist despite negative urine cultures. If left untreated, bladder tumors inevitably enlarge, invade deeper into the muscular layer of the bladder (detrusor muscle), and eventually spread to regional lymph nodes and distant organs. TURBT provides essential tissue to interrupt this disease progression and determine whether the tumor is non-muscle-invasive or muscle-invasive.

3. How the Treatment Works — Mechanism

Cystoscopy and TURBT work by leveraging the natural anatomical path of the lower urinary tract. A rigid or flexible cystoscope—a thin tube equipped with high-definition lenses, fiber-optic lighting, and continuous fluid irrigation channels—is introduced into the external urethral meatus and advanced through the urethra into the bladder. The bladder is gently distended with sterile saline solution to smooth out mucosal folds and allow comprehensive visual inspection of all internal surfaces.

When a tumor is identified, a surgical resectoscope replaces or operates alongside the diagnostic scope. The resectoscope houses a working element with a wire loop charged with high-frequency electrical current (monopolar or bipolar energy) or a specialized laser fiber. The surgeon glides the energized loop across the tumor, systematically shaving it away in thin, controlled slices. This process cuts through the tumor mass down to the healthy muscular base while simultaneously thermal-coagulating (sealing) severed blood vessels to prevent bleeding. The continuous flow of fluid carries tissue fragments into the bladder cavity, where they are washed out using a specialized suction device called an Ellik evacuator and preserved for pathological examination.

4. Types and Variations

Surgical techniques for bladder tumor removal have evolved significantly to maximize pathological accuracy and minimize procedural complications. Clinicians select specific modalities based on tumor size, location, patient comorbidities, and equipment availability.

Procedure Variation	Energy Source / Mechanism	Primary Clinical Indication	Key Clinical Advantages
Monopolar TURBT	Monopolar electrical current; requires non-conductive irrigation fluid (glycine/water).	Standard approach for solitary or small-to-moderate primary bladder lesions.	Established long-term surgical safety profile; widely available globally.
Bipolar TURBT	Bipolar electrical current; utilizes isotonic saline irrigation fluid.	Multiple or large bladder tumors; patients with cardiovascular risks or pacemakers.	Reduced risk of obturator nerve reflex, decreased tissue thermal damage, zero risk of hyponatremia.
En Bloc Resection	Bipolar energy, Holmium:YAG laser, or Thulium laser; excises tumor as a single piece.	Solitary papillary tumors ≤3 cm in size; suspected high-grade lesions.	Preserves intact tissue margins for precise T-stage histological assessment (EAU Guidelines 2023).
Photodynamic Diagnosis (PDD) / Cysview	Fluorescence-guided cystoscopy using intravesical hexaminolevulinate (HAL).	Suspected carcinoma in situ (CIS) or recurrent flat tumors poorly visible under white light.	Significantly improves tumor detection rates and reduces early recurrence (Babjuk et al., 2022).
Narrow Band Imaging (NBI)	Optical filter technology utilizing specific blue and green light wavelengths.	Routine surveillance cystoscopy and TURBT tumor margin mapping.	Enhances mucosal vascular contrast without requiring preoperative dye instillation.

5. Who the Treatment Is For — Indications

The decision to perform cystoscopy and TURBT is governed by established urological guidelines, including those from the European Association of Urology (EAU) and the American Urological Association (AUA). The procedure is indicated across diagnostic, staging, and therapeutic pathways.

• Primary Diagnostic Evaluation: Indicated for individuals presenting with unexplained visible gross hematuria or persistent microscopic hematuria accompanied by abnormal urinary cytology.
• Definitive Surgical Resection of NMIBC: Indicated for complete surgical removal of papillary lesions visually confined to the mucosa (stage Ta) or lamina propria (stage T1).
• Staging of Suspected Muscle-Invasive Disease: Indicated to obtain deep tissue specimens including the detrusor muscle layer to verify whether malignant invasion has reached stage T2 or beyond.
• Second-Look Resection (Re-TURBT): Strongly indicated within 2 to 6 weeks following an initial TURBT if the primary resection was incomplete, if no detrusor muscle was present in the specimen of a high-grade tumor, or for all T1 tumors (AUA/SUO Guidelines 2020).
• Management of Benign Lesions: Indicated for removal and histological confirmation of bladder papillomas, inverted papillomas, cystitis glandularis, or symptomatic urethral/bladder polyps.

6. Who the Treatment Is NOT For — Contraindications

While cystoscopy and TURBT are safe, minimally invasive procedures, specific clinical circumstances represent absolute or relative contraindications requiring stabilization or alternative diagnostic approaches prior to surgery.

• Active, Untreated Urinary Tract Infection (UTI): Absolute contraindication. Surgical instrumentation through infected urine risks inducing urosepsis or bacteremia. Infections must be treated with appropriate targeted antibiotics prior to surgery.
• Uncorrected Coagulopathy or Active Anticoagulation: Relative-to-absolute contraindication depending on bleed risk. Patients with severe bleeding disorders or those unable to temporarily discontinue anticoagulant/antiplatelet therapy face significant risk of uncontrollable intraoperative hemorrhage.
• Severe Urethral Stricture Disease: Relative contraindication. Inability to safely pass the rigid resectoscope through the urethra requires dilating the stricture or considering alternative surgical approaches.
• Small-Capacity, Non-Compliant Bladder: Relative contraindication. An extremely contracted bladder increases the risk of full-thickness thermal perforation during electrosurgical resection.
• Severe Medical Comorbidities Precluding Anesthesia: Absolute contraindication for operative TURBT under general or regional anesthesia; non-surgical palliative measures may be considered.

7. Alternatives and Clinical Comparison

Depending on whether the goal is diagnostic screening, initial treatment, or management of advanced disease, several non-surgical and surgical alternatives exist.

Haupt curative option for invasive disease; requires urinary diversion (neobladder/ileal conduit). Preserves native bladder; requires highly compliant patient and rigorous multi-year follow-up.

Treatment Option	Mechanism of Action	Invasiveness Level	Primary Indication / Timing	Comparative Trade-Offs
Standard TURBT	Endoscopic electrosurgical resection and fulguration.	Minimally invasive (transurethral)	Gold standard for initial diagnosis, staging, and primary therapy of NMIBC.	Requires anesthesia; provides histological tissue; carries risk of bleeding/perforation.
Flexible Office Cystoscopy	Endoscopic visual inspection under local anesthetic gel.	Non-invasive diagnostic	Routine outpatient screening and post-TURBT tumor surveillance.	Diagnostic only; cannot excise large tumors or obtain deep muscle biopsy specimens.
En Bloc Laser Resection	Laser-based circular excision of tumor base.	Minimally invasive (transurethral)	Primary resection of localized tumors ≤3 cm.	Lower bleeding risk and higher margin preservation; requires specialized laser platforms.
Radical Cystectomy	Complete surgical removal of the urinary bladder and regional lymph nodes.	Major open or robotic abdominal surgery	Definitive treatment for muscle-invasive bladder cancer (T2–T4) or refractory NMIBC.
Trimodal Therapy (TMT)	Maximal TURBT combined with concurrent chemotherapy and radiation therapy.	Multimodality non-extirpative therapy	Bladder-preservation alternative for selected patients with muscle-invasive cancer.

8. Pre-Treatment Phase

The pre-treatment phase focuses on clinical optimization, accurate disease mapping, and minimizing procedural complications. Once a clinical suspicion of bladder pathology is established via ultrasound or computed tomography (CT) urography, the formal preoperative process begins.

Patients undergo routine pre-admission laboratory testing, including full blood counts, renal function panels, coagulation studies (INR/PTT), and urine cultures. According to AUA antimicrobial prophylaxis guidelines, any documented bacterial growth in urine must be eradicated with targeted antibiotics prior to entering the operating suite. Anticoagulant and antiplatelet medications (such as warfarin, clopidogrel, rivaroxaban, or apixaban) are systematically reviewed and safely managed—often held for 3 to 7 days before surgery in consultation with the cardiology or hematology team.

Informed consent discussions review procedural goals, the intent to obtain deep muscle tissue, the potential instillation of post-procedure intravesical chemotherapy, and inherent risks such as hematuria, urinary retention, infection, and bladder perforation. Patients fast from solid food for 6 to 8 hours prior to the procedure, although clear fluids may be permitted up to 2 hours before general or spinal anesthesia induction per standardized ERAS (Enhanced Recovery After Surgery) protocols.

9. The Procedure — Step-by-Step Clinical Detail

TURBT is performed in a hospital operating room under strict sterile conditions. The duration typically ranges between 30 and 90 minutes depending on tumor size, number, and complexity.

1. Anesthesia and Positioning: The patient is administered general anesthesia or spinal anesthesia. Once adequate anesthesia is achieved, the patient is placed in the dorsal lithotomy position, with legs supported in padded stirrups.
2. Systematic Diagnostic Cystoscopy: The surgical team performs a thorough visual examination of the entire lower urinary tract using a diagnostic cystoscope. The urologist systematically inspects the urethral mucosa, prostate (in male patients), bladder neck, trigone, ureteral orifices, posterior wall, lateral walls, and dome. Tumor locations, sizes, numbers, and morphological characteristics (papillary vs. solid/flat) are documented.
3. Resectoscope Insertion: The diagnostic scope is replaced with a surgical resectoscope containing a working sheath, optical telescope, and energizable wire loop. Continuous fluid irrigation is initiated to maintain visual clarity and bladder distension.
4. Tumor Resection: The surgeon positions the wire loop behind the tumor and passes energized high-frequency current through the tissue while pulling the loop toward the sheath. The body of the tumor is removed in thin, controlled strips. Resection proceeds systematically down through the mucosal base to reach the underlying connective tissue and superficial detrusor muscle fibers.
5. Deep Muscle Biopsy: To ensure accurate pathological staging, the urologist takes an explicit deep biopsy from the base of the resection site to include clear detrusor muscle tissue, avoiding understaging of invasive disease (EAU Guidelines 2023).
6. Hemostasis and Specimen Retrieval: The surgeon uses rollerball electrocautery or loop fulguration to seal bleeding blood vessels across the resection bed. Tumor chips floating in the bladder are evacuated using an Ellik evacuator, collected, and sent in formalin containers for pathological analysis.
7. Immediate Intravesical Chemotherapy (Optional): If indicated for suspected low- or intermediate-risk NMIBC, a single dose of intravesical chemotherapy (e.g., mitomycin C, gemcitabine, or epirubicin) is instilled into the bladder via a catheter and held for 60 minutes before drainage, provided no deep bladder perforation is present (Sylvester et al., 2016).
8. Catheter Placement: A large-caliber (18–22 French) three-way Foley catheter is inserted into the bladder, and continuous bladder irrigation with sterile saline is initiated if active bleeding requires ongoing clearance.

10. Immediate Post-Procedure Period

Following procedure completion, the patient is transferred to the Post-Anesthesia Care Unit (PACU) for close clinical monitoring. Vital signs, pain levels, and urinary drainage color are monitored by nursing staff.

Mild to moderate hematuria is expected in the immediate recovery phase. If a three-way catheter is placed, continuous bladder irrigation (CBI) runs sterile saline through the bladder to wash out small blood clots and prevent catheter blockage. Once the urine color lightens from deep red to clear pink, the irrigation rate is tapered and eventually discontinued. Oral intake is re-introduced as anesthesia wears off. Oral analgesics and anticholinergic medications (such as oxybutynin or solifenacin) may be prescribed to control uncomfortable bladder spasms caused by the catheter balloon.

Discharge criteria for day-case surgery require stable vital signs, clear or light pink urine output, adequate pain control on oral medications, and successful spontaneous voiding following catheter removal (if the catheter is removed prior to discharge). If significant bleeding or medical comorbidities persist, an overnight hospital stay is arranged.

11. Recovery — Short and Long Term

Full recovery after TURBT typically takes between 2 and 4 weeks, during which the internal bladder wall lining heals completely over the surgical resection site.

Recovery Timeline	Expected Clinical Progress	Activity & Care Guidelines
Days 1–3	Mild hematuria; dysuria; urinary frequency and urgency; urinary catheter may remain in place.	Maintain high fluid intake (2–3 liters of water daily); refrain from driving; take prescribed pain relief and stool softeners.
Days 4–7	Catheter removed if still present; urine color transitions to pale yellow/pink; mild burning persists.	Light domestic walking allowed; avoid heavy lifting (>10 lbs); avoid strenuous exercise or sudden straining.
Days 8–14	Scab over internal bladder wound begins to slough off; transient increase in blood or small dark clots in urine may occur around days 7–10.	Increase fluid intake if urine reddens; refrain from vigorous physical exercise, cycling, and sexual activity.
Weeks 3–4	Urinary frequency and burning fully resolve; internal mucosal lining completely re-epithelializes.	Full return to regular physical exercise, heavy work, travel, and sexual activity pending pathology discussion.
Long-Term	Pathology review completed; risk-stratified surveillance or adjuvant intravesical therapy initiated.	Strict adherence to scheduled surveillance cystoscopy timeline per AUA/EAU guidelines.

12. Risks, Side Effects, and Complications

While transurethral resection is a safe standard procedure, surgical risks exist ranging from minor expected post-procedural side effects to rare serious operative complications.

Severity Category	Possible Complications	Clinical Management & Intervention
Common / Mild (10%–30% of cases)	Transient gross hematuria; dysuria (burning during urination); urinary frequency; mild bladder spasms.	Increased hydration; oral urinary analgesics (e.g., phenazopyridine); short-acting anticholinergic agents.
Uncommon / Moderate (2%–8% of cases)	Urinary tract infection (UTI); blood clot retention in bladder; temporary post-catheter urinary retention.	Targeted oral/IV antibiotics; manual bladder irrigation or temporary re-catheterization.
Rare / Serious (<1%–2% of cases)	Extraperitoneal or intraperitoneal bladder perforation; severe delayed hemorrhage requiring transfusion; urethral stricture; bladder neck contracture; hyponatremia (TURP/TURBT syndrome with monopolar energy).	Prolonged catheter drainage; surgical repair (rarely required for intraperitoneal tears); blood transfusion; cystoscopic stricture dilation.

Bladder Perforation: Occurs when the resectoscope loop cuts through the detrusor muscle into extraperitoneal fat or the peritoneal cavity. Extraperitoneal perforations are typically managed conservatively with prolonged catheter drainage (7–14 days). Intraperitoneal perforations, which occur more frequently during resections at the bladder dome, require prompt laparoscopic or open surgical repair to prevent urine leakage into the abdominal cavity.

Warning Signs Requiring Immediate Emergency Evaluation: Patients must seek immediate medical attention if they experience bright red blood urine with large dark clots, an inability to pass urine for over 4 hours, severe unremitting lower abdominal pain, chills, or a fever exceeding 38.0°C (100.4°F).

13. Lifestyle and Behavioural Considerations

Patient modifications prior to and following TURBT significantly influence healing trajectories, infection rates, and long-term disease outcomes.

Hydration Management: Maintaining a daily fluid intake of 2 to 3 liters of water promotes continuous dilute urine flow. This natural flushing mechanism clears residual blood, prevents clot formation within the bladder, and reduces bacterial colonization risks.

Bowel Function Optimization: Straining during bowel movements increases pelvic venous pressure and can dislodge scabs from the internal bladder healing bed, precipitating secondary hematuria. Patients are advised to utilize dietary fiber supplements and stool softeners pre- and postoperatively.

Cessation of Tobacco Use: Cigarette smoking is the single most significant risk factor for bladder cancer development and recurrence, contributing to over 50% of cases (NCCN Guidelines 2024). Active smoking delivers aromatic amines into the urine that damage urothelial cells. Enrolling in smoking cessation programs directly reduces recurrence risk and improves surgical wound healing.

14. How Outcomes Are Measured

The primary outcomes of TURBT are measured through histological precision, complete tumor clearance, and long-term control of disease recurrence and progression.

Pathological Staging and Grading: Pathology results assess two key variables: cellular grade (Low-Grade vs. High-Grade according to WHO 2016 classification) and anatomical depth of invasion (T-stage). A pathologically complete TURBT requires the presence of detrusor muscle in the histology specimen to confirm the absence of muscle-invasive disease. Missing muscle tissue in high-grade specimens represents an incomplete evaluation and necessitates a repeat resection (re-TURBT) within 2 to 6 weeks (AUA/SUO Guidelines 2020).

Adjuvant Risk Stratification: Patients are stratified into Low, Intermediate, or High Risk groups based on EAU/AUA criteria. High-risk patients (e.g., T1, High-Grade, or extensive CIS) require adjuvant intravesical immunotherapy using Bacillus Calmette-Guérin (BCG) instillations for 1 to 3 years to prevent disease progression to muscle-invasive stages.

15. Recent Advances and Current Standard of Care

The standard of care for TURBT has advanced significantly over the past decade, driven by innovations in optical imaging, energy delivery, and pathological techniques.

Enhanced Visibility Technologies: Conventional white-light cystoscopy can miss flat dysplastic lesions and small papillary satellites. Photodynamic Diagnosis (PDD), which utilizes instillation of hexaminolevulinate (HAL) to induce fluorescent accumulation in malignant cells under blue light, has demonstrated a statistically significant reduction in 12-month tumor recurrence rates compared to standard white light (Babjuk et al., 2022). Narrow Band Imaging (NBI) offers an alternative optical filter system that highlights hypervascular tumor architecture without contrast agents.

En Bloc Resection Techniques: Traditional TURBT removes tumors piecemeal, which can fragment tumor architecture and potentially cause tumor cell seeding. Modern en bloc resection of bladder tumor (ERBT) uses specialized laser fibers (Thulium:YAG or Holmium:YAG) or hydro-dissection tools to scoop the tumor out as an intact single specimen containing mucosal margins and deep muscle. Clinical trials demonstrate cleaner histological margins, lower thermal artifact, and reduced rates of bladder perforation with en bloc approaches (Gillies et al., 2019).

16. Common Myths and Misconceptions

Myth: A TURBT procedure completely cures bladder cancer permanently.
Reality: While TURBT effectively removes visible tumors, non-muscle-invasive bladder cancer has a high historical recurrence rate ranging from 30% to 70% within 5 years (Sylvester et al., 2016). Lifelong or multi-year cystoscopic surveillance is essential to detect and treat microscopic recurrences early.

Myth: Having blood in the urine after TURBT always means the cancer has immediately returned.
Reality: Transient hematuria is a expected part of the normal surgical healing process. Minor bleeding often increases around 7 to 10 days post-surgery when internal scabs slough off the bladder wall, which is normal unless heavy clotting or urinary blockages occur.

Myth: TURBT requires a major surgical incision across the lower abdomen.
Reality: TURBT is performed entirely transurethrally using natural body passages. No external skin incisions or scars are created.

Myth: An outpatient cystoscopy can fully stage bladder cancer without needing TURBT.
Reality: Office flexible cystoscopy can only visually detect lesions. Definitive pathological staging requires surgical TURBT under anesthesia to obtain deep tissue samples including the detrusor muscle layer.

Myth: Intravesical chemotherapy or BCG therapy is the same as systemic intravenous chemotherapy.
Reality: Intravesical therapies are placed directly into the bladder via a soft catheter and washed out after 1 to 2 hours. Because the drug is not absorbed into the bloodstream in significant amounts, patients do not experience systemic side effects like hair loss or severe systemic nausea.

Myth: You can skip follow-up cystoscopies if you feel completely healthy and have no pain.
Reality: Early recurrent bladder tumors rarely cause pain or visible symptoms. Relying on physical symptoms alone delays detection until tumors become larger or invade deeper layers (AUA/SUO Guidelines 2020).

17. Frequently Asked Questions

Is cystoscopy and TURBT painful?

Diagnostic office flexible cystoscopy causes mild discomfort and pressure, which is minimized using topical anesthetic gel. TURBT is performed under general or spinal anesthesia, ensuring you feel no pain during the procedure. After surgery, mild burning during urination and bladder spasms are common for several days but are well managed with prescribed oral medications.

How long does a TURBT procedure take?

The operative duration of a TURBT typically ranges between 30 and 90 minutes depending on the number, size, and anatomical locations of the bladder tumors. Pre-operative preparation and post-anesthesia recovery add several hours to the total hospital stay.

Will I need to stay in the hospital overnight?

Many patients undergo TURBT as a day-case procedure and return home the same day once urine color clears and spontaneous voiding is confirmed. However, if you have large tumors, require continuous bladder irrigation, or have underlying medical conditions, an overnight hospital stay may be recommended.

How long will I need a urinary catheter after TURBT?

A Foley catheter is typically left in place for 24 to 72 hours postoperatively to ensure clear urinary drainage and allow the bladder lining to rest. In minor resections, the catheter may be removed on the same day, whereas complex resections or small perforations may require catheterization for 5 to 7 days.

When will I get my pathology biopsy results?

Histopathological analysis of resected tissue typically takes between 7 and 14 days. The detailed pathology report identifies tumor type, cellular grade (low vs. high grade), and muscle invasion status, which determines your definitive cancer stage and long-term care plan.

What is a second-look TURBT (Re-TURBT) and why is it needed?

A second-look TURBT is a repeat procedure performed 2 to 6 weeks after the initial surgery. Clinical guidelines recommend re-TURBT for all high-grade T1 tumors or incomplete initial resections to ensure no invasive cancer remains and to verify deep staging accuracy (EAU Guidelines 2023).

When can I return to work and normal daily activities?

Most individuals return to sedentary desk work and light daily activities within 5 to 7 days post-procedure. Strenuous physical labor, heavy lifting (>10 lbs), vigorous exercise, and driving should be avoided for 2 to 3 weeks until gross hematuria has completely resolved.

How long should I wait before resuming sexual activity?

Patients are generally advised to abstain from sexual activity for 2 to 3 weeks following TURBT. Resuming sexual activity prematurely can cause mechanical stress on the healing bladder neck and trigger secondary bleeding or infection.

Why do I need intravesical chemotherapy right after surgery?

Instilling a single dose of intravesical chemotherapy (such as mitomycin C or gemcitabine) into the bladder within 24 hours of TURBT destroys floating cancer cells dislodged during resection. This single instillation reduces the 5-year tumor recurrence rate by up to 35% in low-to-intermediate risk disease (Sylvester et al., 2016).

What are the signs of a post-procedure urinary tract infection?

Signs of a urinary tract infection after TURBT include cloudy or foul-smelling urine, severe worsening burning during urination, new onset lower abdominal pain, chills, and a fever above 38.0°C (100.4°F). These symptoms require prompt evaluation and antibiotic treatment.

How often will I need follow-up cystoscopy after TURBT?

Surveillance schedules depend on your risk category. Low-risk patients typically undergo cystoscopy at 3 months, then annually for 5 years. High-risk patients undergo cystoscopy every 3 months for the first 2 years, every 6 months for the next 2 years, and annually thereafter (AUA/SUO Guidelines 2020).

Can I travel or fly after having a TURBT?

Short travel is generally safe after catheter removal, but long-distance travel or flying should be delayed for 2 weeks post-TURBT. Sitting for prolonged periods increases pelvic congestion, and traveling far from medical care is risky if delayed bleeding or urinary retention occurs.

What happens if the pathology report shows muscle-invasive bladder cancer?

If the resected detrusor muscle contains malignant cells (stage T2 or higher), the cancer has invaded the muscular wall. Treatment plans transition from localized bladder therapies to radical cystectomy (bladder removal) or trimodal bladder-preserving therapy combining chemoradiation (NCCN Guidelines 2024).